Skin Cancer Incidence in Young Adults Decreasing for the First Time in Sweden
For the first time, Sweden reports a decrease in skin cancer rates among adults under 50, according to a new study.
Complete the form below to unlock access to ALL audio articles.
The risk of skin cancer for adults under the age of 50 is now decreasing for the first time in Sweden, according to a study from Karolinska Institutet published in JAMA Dermatology.
The risk of skin cancer, malignant melanoma, now appears to be decreasing in Sweden - at least in those under 50, according to a new study.
“We can see a trend break in young adults around 2015 where the incidence curves are falling,” says first author Hildur Helgadottir, senior consultant and associate professor of oncology at the Department of Oncology-Pathology, Karolinska Institutet.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREEShe and her research colleagues have analyzed data from the Swedish Melanoma Registry and followed melanoma incidence and mortality for different age segments over time. This means that they have compared individuals in a certain age range at one point in time with individuals in the same age range at another point in time.
The results show that the new-onset curves for people over 50 years of age are steadily increasing, but for the age groups younger than 50 years, the new-onset curves started to decrease around 2015.
“This is the first time we see this in Sweden, and we are actually the first European country to report a decline,” says Hildur Helgadottir.
Introduction of new oncological drugs
In terms of mortality, the curves have also turned downwards for ages up to 59, but not for those over 60. Hildur Helgadottir believes that the decrease in mortality in the younger groups is due both to a reduction in the incidence of the disease and to the introduction of new oncological drugs that have improved the prognosis for the disease. She believes that the fact that mortality is not decreasing in the elderly is because the incidence of the disease is still so high in this group.
“The question is why the risk of melanoma has decreased. We have not directly analyzed the causes in our study, but we have hypotheses about factors that we believe have interacted,” says Hildur Helgadottir.
“There are four main factors,” she says.
The first is increased awareness of sun protection.
“The first national 'Sun Safe' campaign in the 1990s specifically highlighted the importance of protecting children. About 20 years later, we believe that this has led to a reduction in the incidence of the disease in younger adults,” says Hildur Helgadottir.
Another factor is that access to sunbeds has decreased drastically. Since 2018, there has been an 18-year age limit on sunbeds, but the number of public sunbeds decreased much earlier.
Young people spend more time indoors
Third, mobile phones and computers mean that children and young people are spending more time indoors and are not exposed to sunlight in the same way today.
Finally, immigration means that there are more individuals in Sweden with darker pigmentation who can tolerate the sun better.
“We see that it is necessary to continue the work of emphasizing the importance of sun protection so that the reduction of melanoma in younger people is maintained and that the incidence will eventually also decrease in older people,” says Hildur Helgadottir.
Hildur Helgadottir points out how necessary it is to continue to emphasize the importance of sun protection so that the reduction of melanoma in younger people is sustained and that the incidence will eventually decrease in older people as well.
“We are having an unusually warm and sunny September. It is important to remember that from April to September the sun can be strong and you should be careful,” says Hildur Helgadottir.
Reference: Helgadottir H, Mikiver R, Schultz K, et al. Melanoma incidence and mortality trends in Sweden. JAMA Dermatol. 2024. doi: 10.1001/jamadermatol.2024.3514
This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source. Our press release publishing policy can be accessed here.